PepGen Inc. (Nasdaq: PEPG) has recently announced the appointment of Afsaneh Mohebbi, Ph.D., as Senior Vice President, Portfolio and Program Management, and Dave Borah, CFA, as Senior Vice President, Investor Relations and Corporate Communications. The company, a clinical-stage biotechnology firm focusing on oligonucleotide therapies for severe neuromuscular and neurological diseases, expressed enthusiasm for the expertise and contributions these new team members are expected to bring.
Dr. Mohebbi's extensive experience in advancing candidates from preclinical stages to registration, combined with her strong track record in leading cross-functional teams, is expected to be instrumental in guiding PepGen's pipeline of products through the clinic. Her previous roles include Vice President, Program Management, Rare Diseases at Agios Pharmaceuticals, Head of Program and Alliance Management at BIND Therapeutics, and Senior Program Executive, Rare Diseases at Shire Human Genetic Therapies.
On the other hand, Mr. Borah's deep industry insights and experience, including his robust network of investors and analysts, are anticipated to be crucial for maintaining strong communications and relationships with all stakeholders as PepGen develops innovative drug candidates for people living with neuromuscular disorders. His previous role as Senior Vice President of Investor Relations and Corporate Affairs at Mural Oncology and his buy-side experience in equity research positions further add to his qualifications.
The company, which is preparing for numerous key clinical milestones in the second half of this year, believes that the addition of these two senior team members will enhance its expertise in critical areas of the organization. PepGen's Enhanced Delivery Oligonucleotide (EDO) platform, founded on over a decade of research and development, leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. The company aims to generate a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases.
Following these announcements, the company's shares moved -8.9%, and are now trading at a price of $16.32. For the full picture, make sure to review PepGen's 8-K report.
